http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Jung, J H,Cho, H K,Krstic, V D 대한금속재료학회(대한금속학회) 2001 METALS AND MATERIALS International Vol.7 No.1
In order to develop inert matrix material, evaluation of physical and chemical properties required for sintered nuclear fuel candidate materials were performed for more appropriate candidate material selection. Active research is being carried out to develop a new inert matrix material, e.g. ZrO₂, MgAl₂O₄, ZrSiO₄ and SiC, that prohibits the formation of Pu and actinides. Based on the experimental results, pressureless sintered SiC was considered to be the most appropriate candidate material. Microstructure and thermal conductivity changes were examined of the porous SiC. Effective thermal conductivity decreased by increasing porosity and decreasing the ratio between gas thermal conductivity within pores and sintered material thermal conductivity. With same porosity level, pore size and distribution have little effect on effective thermal conductivity.
Radioactivity of biological samples of patients treated with 90Y-DOTATOC
Jeremic Marija Z.,Matovic Milovan D.,Mijatovic Nenad R.,Pantovic Suzana B.,Krstic Dragana Z.,Miladinovic Tatjana B.,Nikezic Dragoslav R. 한국원자력학회 2023 Nuclear Engineering and Technology Vol.55 No.10
Dosimetric studies in Nuclear Medicine are very important, especially with new therapeutic methods, the number of which has increased significantly with the Theranostic approach (determining diagnostictherapeutic pairs where similar molecules are labelled with different isotopes in order to diagnose and treat malignant diseases). Peptide receptor radionuclide therapy (PRRT) has been used successfully for many years to treat neuroendocrine tumors (NET). 90Y-DOTATOC is one of the radiopharmaceuticals used frequently in this type of therapy. In this work, blood and urine samples from 13 patients treated with 90Y-DOTATOC were measured by a liquid scintillation beta counter (LSC). Calibration of the beta counter for this type of measurement was done and all results are presented in the paper. The presented paper also provides a methodology for determining the measurement uncertainty for this type of measurement. Immediately after the administration of radiopharmaceuticals, the activity in the blood was different from 6.31% to 88.9% of the applied radioactivity, while 3 h after the termination of the application, the average value of radiopharmaceuticals in the blood was only 3.84%. The activity in the excreted urine depended on the time when the patients urinated after the therapy. It was measured that as much as 58% of the applied radioactivity was excreted in the first urine after the therapy in a patient who urinated 4.5 h after the completed application of the therapy. In most patients, the highest urine activity was in the first 10 h after the application, while the activities after that time were negligibly low. The described methodology of measuring and evaluating activity in blood and excreted urine can be applied to other radiopharmaceuticals used in nuclear medicine. It could be useful for researchers for dosimetric assessments in clinical application of PRRT